Getting Pharmaceutical R&D Back on Target

Overview

Journal Nat Chem Biol

Specialties Biochemistry
Biology
Chemistry

Date 2011 May 19

PMID 21587251

Citations 74

Authors

Mark E Bunnage

Affiliations

Soon will be listed here.

Citing Articles

Mutate and Conjugate: A Method to Enable Rapid In-Cell Target Validation.

Thomas A, Serafini M, Grant E, Coombs E, Bluck J, Schiedel M ACS Chem Biol. 2023; 18(11):2405-2417.

PMID: 37874862 PMC: 10660337. DOI: 10.1021/acschembio.3c00437.

Integrating inflammatory biomarker analysis and artificial-intelligence-enabled image-based profiling to identify drug targets for intestinal fibrosis.

Yu S, Kalinin A, Paraskevopoulou M, Maruggi M, Cheng J, Tang J Cell Chem Biol. 2023; 30(9):1169-1182.e8.

PMID: 37437569 PMC: 10529501. DOI: 10.1016/j.chembiol.2023.06.014.

Prioritization and functional validation of target genes from single-cell transcriptomics studies.

Sokol L, Cuypers A, Truong A, Bouche A, Brepoels K, Souffreau J Commun Biol. 2023; 6(1):648.

PMID: 37330599 PMC: 10276815. DOI: 10.1038/s42003-023-05006-7.

An electroaffinity labelling platform for chemoproteomic-based target identification.

Kawamata Y, Ryu K, Hermann G, Sandahl A, Vantourout J, Olow A Nat Chem. 2023; 15(9):1267-1275.

PMID: 37322100 DOI: 10.1038/s41557-023-01240-y.

Experimental strategies to improve drug-target identification in mass spectrometry-based thermal stability assays.

Phaneuf C, Aizikov K, Grinfeld D, Kreutzmann A, Mourad D, Lange O Commun Chem. 2023; 6(1):64.

PMID: 37024568 PMC: 10079678. DOI: 10.1038/s42004-023-00861-1.

References

Kromdijk W, Huitema A, Mulder J . Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother. 2010; 11(7):1215-23. DOI: 10.1517/14656561003801081. View

Wells J, McClendon C . Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-9. DOI: 10.1038/nature06526. View

Edwards A, Isserlin R, Bader G, Frye S, Willson T, Yu F . Too many roads not taken. Nature. 2011; 470(7333):163-5. DOI: 10.1038/470163a. View

Bonetta L . Protein-protein interactions: Interactome under construction. Nature. 2010; 468(7325):851-4. DOI: 10.1038/468851a. View

Frye S . The art of the chemical probe. Nat Chem Biol. 2010; 6(3):159-161. DOI: 10.1038/nchembio.296. View

De Luca L, Ferro S, Gitto R, Letizia Barreca M, Agnello S, Christ F . Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem. 2010; 18(21):7515-21. DOI: 10.1016/j.bmc.2010.08.051. View

Buchwald P . Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life. 2010; 62(10):724-31. DOI: 10.1002/iub.383. View

Nicodeme E, Jeffrey K, Schaefer U, Beinke S, Dewell S, Chung C . Suppression of inflammation by a synthetic histone mimic. Nature. 2010; 468(7327):1119-23. PMC: 5415086. DOI: 10.1038/nature09589. View

Hopkins A, Groom C . The druggable genome. Nat Rev Drug Discov. 2002; 1(9):727-30. DOI: 10.1038/nrd892. View

10.

Heal W, Tam Dang T, Tate E . Activity-based probes: discovering new biology and new drug targets. Chem Soc Rev. 2010; 40(1):246-57. DOI: 10.1039/c0cs00004c. View

11.

Adams C, Brantner V . Spending on new drug development1. Health Econ. 2009; 19(2):130-41. DOI: 10.1002/hec.1454. View

12.

Stumpf M, Thorne T, de Silva E, Stewart R, An H, Lappe M . Estimating the size of the human interactome. Proc Natl Acad Sci U S A. 2008; 105(19):6959-64. PMC: 2383957. DOI: 10.1073/pnas.0708078105. View

13.

Driggers E, Hale S, Lee J, Terrett N . The exploration of macrocycles for drug discovery--an underexploited structural class. Nat Rev Drug Discov. 2008; 7(7):608-24. DOI: 10.1038/nrd2590. View

14.

Cohen P, Tcherpakov M . Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell. 2010; 143(5):686-93. DOI: 10.1016/j.cell.2010.11.016. View

15.

Bedford L, Lowe J, Dick L, Mayer R, Brownell J . Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2010; 10(1):29-46. PMC: 7097807. DOI: 10.1038/nrd3321. View

16.

Venkatesan K, Rual J, Vazquez A, Stelzl U, Lemmens I, Hirozane-Kishikawa T . An empirical framework for binary interactome mapping. Nat Methods. 2008; 6(1):83-90. PMC: 2872561. DOI: 10.1038/nmeth.1280. View

17.

Kritzer J . Stapled peptides: Magic bullets in nature's arsenal. Nat Chem Biol. 2010; 6(8):566-7. DOI: 10.1038/nchembio.407. View

18.

Drenth J, Waxman S . Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. 2007; 117(12):3603-9. PMC: 2096434. DOI: 10.1172/JCI33297. View

19.

Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith W, Fedorov O . Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-73. PMC: 3010259. DOI: 10.1038/nature09504. View

20.

Metz J, Hajduk P . Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. Curr Opin Chem Biol. 2010; 14(4):498-504. DOI: 10.1016/j.cbpa.2010.06.166. View